NEUROCRINE BIOSCIENCES INC 4

Chief Regulatory Officer Ingrid Delaet exercised and sold 14,571 shares of Neurocrine Biosciences Inc. common stock in cashless option exercises over July 7–9, 2026, leaving her direct holdings unchanged at 16,225 shares.

On July 7, 8, and 9, 2026, Neurocrine Biosciences Inc. Chief Regulatory Officer Ingrid Delaet exercised non-qualified stock options for a total of 14,571 shares of common stock at an exercise price of $103.52 per share and sold an equal total of 14,571 shares in same-day transactions under a pre-arranged Rule 10b5-1 trading plan. Specifically, she exercised and acquired 3,401 shares on July 7, 2,737 shares on July 8, and 8,433 shares on July 9 at $103.52, and on each corresponding date sold the same number of shares at weighted average sale prices of approximately $178.57, $178.54, and $178.72, respectively. These trades appear structured as cashless exercises, with the sales covering the exercised shares, and her direct ownership in Neurocrine common stock remained at 16,225 shares after each day’s transactions, implying no net change in her reported direct shareholdings despite realizing a substantial spread between the option exercise and market prices.

Filing Facts

CIK

914475

Ticker

NBIX

Form

4

Source Type

fda

Accession

0001965808-26-000011

Alert Tier

6